EUCTR2004-003000-37-BE进行中（未招募）1 期
A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) compared to Atorvastatin 20mg in Patients with Type II Diabetes. - Eze/Simva Switch Study in Diabetics
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •a.Patient is currently treated with atorvastatin 10 mg for at least 6 weeks.
- •b.Patient has Diabetes Mellitus, Type II.
- •c.Patient has HbA1C of less than or equal to 10.0%.
- •d.Patient having liver transaminases (ALT, AST) less than or equal to 50% above the upper limit of normal at Visit 1, with no active liver disease, and/or creatine kinase (CK) less than or equal to 50% above the upper limit of normal.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a.Female patient receiving hormone therapy not on a stable dose and regimen for at least 8 weeks prior to Visit 1 or is unwilling to continue the same regimen throughout the study.
- •b.Patients with alcohol consumption > 14 drink per week. (A drink is: a can of beer, glass of wine, or single measure of spirits.)
- •c.Patients who are pregnant or lactating.
- •d.Patients who have been treated with any other investigational drug within 3 months of Visit 1. (If < 3 month, contact the Clinical Monitor for a case-by-case evaluation.)
- •e.Any condition or situation which, in the opinion of the investigator, might pose a risk to the patient or interfere with participation in the study.
- •PROHIBITED MEDICAL CONDITIONS:
- •f.Congestive heart failure defined by NYHA Class III or IV.
- •g.Myocardial infarction, coronary artery bypass surgery, or angioplasty within 3 months prior to Visit 1.
- •h.Uncontrolled hypertension (treated or untreated) with systolic blood pressure > 160 mm Hg or diastolic > 100 mm Hg at Visit 1.
- •i.Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins (i.e. secondary causes of hyperlipidemia) or secondary hypercholesterolemia due to hypothyroidism, (T4 < 4 ?g/dL) at Visit 1. Note: Patient with a history of hypothyroidism, who is on stable therapy of thyroid hormone replacement for at least 6 weeks is eligible for enrollment if TSH level is within normal limits at screening Visit 1.
- •j.Impaired renal function [creatinine ? 177 ?mol/L (? 2.0 mg/dL)] or nephrotic syndrome at Visit 1.
- •k.Disorder of the hematologic, digestive, or central nervous systems including cerebrovascular disease and degenerative disease that would limit study evaluation or participation.
- •l.Patient who is known HIV positive.
- •m.Cancer within the past 5 years (except for successfully treated basal and squamous cell carcinoma).
- •n.History of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.
- •PROHIBITED CONCOMITANT THERAPIES:
- •o.Medications that are potent inhibitors of CYP3A4, including cyclosporin, systemic itraconazole or ketoconazole, erythromycin, telithromycin or clarithromycin, nefazodone, protease inhibitors. In addition, patients should not take amiodarone, verapamil, or danazol. Patient is consuming > 1 quart of grapefruit juice/day.
- •p.Lipid-lowering agents including fish oils, Cholestin, bile-acid sequestrants, other HMG-CoA reductase inhibitors, and niacin (>200 mg/day) taken within 6 weeks and fibrates within 8 weeks prior to randomization at Visit 2 (Day 1).
- •q.Oral corticosteroids (unless used as replacement therapy for pituitary/adrenal disease and on a stable regimen for at least 6 weeks prior to Visit 1).
- •r.Patient is not stable on cardiovascular medications, such as beta-blockers, calcium-channel blockers, ACE inhibitors, nitrates, a-adrenergic blockers, thiazide diuretics or anticoagulants (i.e. warfarin), or psyllium, other fiber-based laxatives, and/or an OTC therapy known to affect serum lipid (phytosterol margarine) for at least 6-weeks. Note: Patient will be eligible to participate if on a
研究者
相似试验
进行中（未招募）
不适用
A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) compared to Atorvastatin 20mg in Patients with Type II Diabetes. - Eze/Simva Switch Study in DiabeticsHypercholesterolemia in patients with Type II DiabetesMedDRA version: 7.0Level: LLTClassification code 10020603EUCTR2004-003000-37-DEMerck & Co. Inc.
进行中（未招募）
1 期
A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) compared to Atorvastatin 20mg in Patients with Type II Diabetes. - Eze/Simva Switch Study in DiabeticsEUCTR2004-003000-37-LTMerck & Co., Inc.500
进行中（未招募）
不适用
A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin 10mg/20mg and Ezetimibe/Simvastatin 10mg/40mg compared to Atorvastatin 20mg in Patients with Type II Diabetes.hypercholesterolemyMedDRA version: 6.1Level: HLTClassification code 10014476EUCTR2004-003000-37-ITMERCK SHARP DOHME500
进行中（未招募）
1 期
A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) compared to Atorvastatin 20mg in Patients with Type II Diabetes. - Eze/Simva Switch Study in DiabeticsHypercholesterolemia in patients with Type II DiabetesMedDRA version: 7.0 Level: LLT Classification code 10020603EUCTR2004-003000-37-ESMerck & Co. Inc.250
进行中（未招募）
不适用
A Multicenter, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Crohn's DiseaseEUCTR2006-004814-41-NLAbbott GmbH & Co. KG184